Executive Leadership
Current Scientific Advisory Board
“Parkinson’s Disease presents a challenging scientific problem as well as a major unmet medical need. The ASAP Initiative offers an opportunity for major innovative impact on both fronts in this important area.”
Planning Advisory Council
With thanks to ASAP’s founding Advisory Council for their input and guidance in development of the strategic roadmap.
James Beck, PhD
Chief Scientific Officer, VP, Scientific Affairs, Parkinson’s Foundation
Patrik Brundin, MD, PhD
Van Andel Research Institute Center for Neurodegenerative Science
Pietro De Camilli, MD
Kavli Institute for Neuroscience at Yale School of Medicine
Marie-Françoise Chesselet, MD, PhD
Van Andel Institute Center for Neurodegenerative Science
Martin Citron, PhD
UCB Pharma
David Dexter, PhD
Parkinson’s UK, Imperial College London
Ted Dawson MD, PhD
Johns Hopkins University School of Medicine
Thomas Gasser, MD, PhD
Hertie Institute for Clinical Brain Research
Magali Haas, MD, PhD
Cohen Veterans Bioscience
Karl Kieburtz, MD, MPH
University of Rochester Medical Center
Walter Koroshetz, MD
National Institute of Neurological Disease and Stroke
Robert Malenka, MD, PhD
Stanford University School of Medicine
Kelsey Martin, MD, PhD
David Geffen School of Medicine at UCLA
Eliezer Masliah, MD
National Institute of Aging, NIH
K. Kimberly McCleary
The Kith Collective
Karoly Nikolich, PhD
Alkahest
C. Warren Olanow, MD
Mt. Sinai School of Medicine
Bernardo Sabatini, MD, PhD
Harvard Medical School
Randy Schekman, PhD
University of California, Berkeley
Darryle Schoepp, PhD
Merck
Todd Sherer, PhD
The Michael J. Fox Foundation for Parkinson’s Research
Andrew Singleton, PhD
National Institute of Aging, NIH
Beth Stevens, PhD
Harvard Medical School
David Sulzer, PhD
Columbia University Medical Center
Huda Zoghbi, MD
Baylor College of Medicine
